Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

NCT00673049 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

583

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Carcinoma, Adenosquamous Cell

Interventions

DRUG: CP 751,871 (Figitumumab)
DRUG: Erlotinib
DRUG: Erlotinib

Sponsor

Pfizer